| Literature DB >> 34916930 |
Abstract
Social species form organizations that support individuals because the consequent social behaviors help these organisms survive. The isolation of these individuals may be a stressor. We reviewed the potential mechanisms of the effects of social isolation on cholinergic signaling and vice versa how changes in cholinergic signaling affect changes due to social isolation.There are two important problems regarding this topic. First, isolation schemes differ in their duration (1-165 days) and initiation (immediately after birth to adulthood). Second, there is an important problem that is generally not considered when studying the role of the cholinergic system in neurobehavioral correlates: muscarinic and nicotinic receptor subtypes do not differ sufficiently in their affinity for orthosteric site agonists and antagonists. Some potential cholinesterase inhibitors also affect other targets, such as receptors or other neurotransmitter systems. Therefore, the role of the cholinergic system in social isolation should be carefully considered, and multiple receptor systems may be involved in the central nervous system response, although some subtypes are involved in specific functions. To determine the role of a specific receptor subtype, the presence of a specific subtype in the central nervous system should be determined using search in knockout studies with the careful application of specific agonists/antagonists.Entities:
Keywords: cholinergic signaling; interactome; muscarinic receptors; nicotinic receptors; social isolation; social stress
Year: 2021 PMID: 34916930 PMCID: PMC8670609 DOI: 10.3389/fphar.2021.716460
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
The parameters of social isolation.
| Start of isolation | Number of isolation episodes | Duration of isolation | Species | References |
|---|---|---|---|---|
| 26–28 days | 1 (3 days before drug study) | 21 +3 days (aggressors)/1, 7, 14, 21 days | mouse |
|
| birth | 1 | 20, 30, 60 days | cat |
|
| 25th day | 1 | 165 days | mouse |
|
| adulthood | 1 | 30 days | rat |
|
| 4th week | 1 | 3 months | rat |
|
| weaning | 1 | 6–7 weeks | mice |
|
| 3rd day | 1 | 3rd - 14th day for 16 h/day | rat |
|
| weaning | 1 | 4, 8 weeks | rat |
|
| weaning | 1 | 6 weeks | rat |
|
| weaning (day 28) | 1 | 8 weeks | rat | ( |
| 2 months | 1 | 2 weeks | mouse |
|
| adulthood | 1 | 7 days | rat |
|
| weaning | 1 | 30 days | rat |
|
| weaning | 1 | 6 weeks | rat |
|
| weaning (day 30) | 1 | 60 days | gerbil |
|
| weaning (day 21) | 1 | 1 year | rat |
|
| days 33–48 or 65–80 | 1 | 1 h | rat |
|
| 3 weeks | 1 | more than 6 weeks | mouse |
|
| adulthood | 1 | 1 month | mouse |
|
| 12 weeks | 1 | 16 weeks | mouse |
|
| 3 weeks | 1 | 6 weeks | mouse |
|
| adulthood | 1 | 2 h | rat | ( |
| 3 months | 1 | 12 weeks | rat |
|
| 4 weeks | 1 | 6 weeks | mouse |
|
| adulthood (day 38) | 1 | 13 days (until day 51) | rat |
|
| 4 weeks | 1 (repeated between tests) | 2 + 1 weeks | mouse |
|
| 2 + 1 weeks +1 + 4 days | ||||
| not given | 1 | 6 weeks | mouse |
|
| adulthood | 1 | 4 weeks | prairie voles |
|
| adulthood | 1 (repeated between tests) | 4 weeks + 11 days | mouse |
|
| adulthood | 1 (repeated between tests) | 70 days (with tests in between) | rat |
|
Please note that adult rats/mice differ in strain and weight (e.g., age) at the beginning of the experiment, which is not specifically given in this table. The table illustrates the variability in applied social isolation and does not represent a full view of isolation schemes (see text for details).
Rats were sleep deprived.
FIGURE 1Cholinergic signaling. See legend for symbol explanation.
The effects of drugs on specific cholinergic mechanisms.
| Drug | Activity | Muscarinic receptors | Nicotinic receptors | Cholinesterases (ChEs) | Other targets | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M1 | M2 | M3 | M4 | M5 | α2 | α4 | α5 | α7 | AChE | BuChE | |||
|
| |||||||||||||
| Acetylcholine | agonist | 4.3–4.9 | 6.4 | 5.6 | 4.5–5.6 | 6.1 | 7.96 | 4–8.77 | 4.06–6.3 | — | — | ||
|
| |||||||||||||
| Carbachol | agonist | 3.2–5.3 | 4.2–5.7 | 4.0–4.4 | 4.3–4.9 | 4.9 | — | 6.12 | 4.18 | not cleaved by ChEs | — | ||
| Pilocarpine | agonist | 4.9–5.1 | 4.9 | 5.1 | 5.2 | 5.0 | — | — | — | — | — | — | — |
| Oxotremorine | agonist | 5.5–6.0 | 5.0–6.6 | 5.3 | 5.2 | 5.1–7.26 | — | — | — | — | 5.82–8.77 | — | — |
| Oxotremorine-M | agonist | 5.1–5.6 | 4.9 | 5.1 | 5.2 | — | — | — | — | — | — | — | — |
| Arecoline | agonist | 5.7 | 5.2 | 5.4 | 5.5 | — | 6.65 | 6.57 | 6.65 | — | — | — | CACNA1C |
| Bethanechol | agonist | 4.0 | 4.0 | 4.2 | 4.0 | — | — | — | — | — | — | — | — |
| Pirenzepine | antagonist |
| 6.3–6.7 | 6.7–7.1 |
| 6.2–7.1 | — | — | — | — | — | — | — |
| Atropine | antagonist | 8.5–9.6 | 9.0–9.1 | 8.9–9.8 | 8.7–9.9 | 9.3–9.7 | — | — | 4.49 | — | 9.15–9.46 | — | α1D,2A-AR, 5-HT1A,2C, SLC22A1, glycine |
| Benzatropine | antagonist | 9.0 | 8.6 | 8.89–9.57 | 8.62–9.48 | 8.84–8.69 | — | — | — | — | — | — | D3DR, α1A,B,D-AR α2A,B,C-AR,DAT, H1R, H2R, NET, 5-HT2A,B,C, 5-HT6,SERT,σOR |
| Scopolamine | antagonist | 9.0 | 8.7 | 9.4 | 9.5 | — | — | — | — | — | — | — | — |
| Methylscopolamine | antagonist | 9.9 | — | 10.4 | — | — | — | — | — | — | — | — | — |
| N-desmethylclozapine | allosteric modulator | 6.8–7.3 | — | — | — | — | — | — | — | — | — | — | 5-HT2, 5-HT6, 5-HT7 |
|
| — | ||||||||||||
| Nicotine | agonist | — | — | — | — | — | 7.92 | 6.89–8.66 | — | 4.04–4.87 | — | — | TRPA1, Kv4.3,5-HT3, σOR, SLC22A1, SLC22A2 |
| Methyllycaconitine | antagonist | — | — | — | — | — | — | — | — | 8.72 | — | — | — |
| Mecamylamine | channel blocker | — | — | — | — | — | — | 5.3–6.5 | — | 4.8 | — | — | other α subunits (α1, α3, α6) |
|
| |||||||||||||
| Rivastigmine | — | — | — | — | — | — | — | — | — | — | 5.4 |
| SERT |
| Physostigmine | — | 4.43 | 5.87 | 5.54 | 7.6–7.8 | 7.6–7.8 | CYP2D6 | ||||||
| Pyridostigmine | — | 6.09 | 5.70 | 6.4 | 6.1 | — | |||||||
| Galantamine | — | 5.05 | — | 5.0 | — | 6.05 | 6.3 | 4.55–6.72 | NMDAε2 | ||||
| Donepezil | — | 6.08 | 4.52 | 7.7–8.3 | 4.82–7.7 | ACAT, BACE 1, ChAc, H3R, MAO B, σ1, σOR | |||||||
| Tacrine | — | 5.7 (allosteric) | 5.7 (allosteric) | E | — | — | 5.05–5.4 | 7.5 | 7.2 | ACAT, α1A-AR, β-amyloid A4 protein, CB1R, CB2R, ChAc, CYP2D6, DAT, GluN1, GluN2, MAO A, B, HNMT, NET, SERT, SLC22A1 | |||
The numbers show pKi. Only selected subunits are shown for NRs. Specificity (i.e., higher affinity than to other subtypes) is shown by a bold character. Please note that higher affinity means higher pKi. If the pKi was not given or could be computed, then the effects are shown as “E”. Unavailable data are shown as blank spaces. Data are from or adapted from (Pascuzzo et al., 1984; Cantí et al., 1998; Becerra et al., 2001; Lockhart et al., 2001; Samochocki et al., 2003; Harada et al., 2010; Alexander et al., 2017a; Alexander et al., 2017b; Myslivecek, 2019) and the IUPHAR/BPS Guide to Pharmacology (www.guidetophamacology.org). The activity represents the main effect of a specific ligand.
Data available for all muscarinic receptor subtypes without specification.
Data from electric eel.
Data from muscle (frog, rat). CANCA1C, voltage-dependent L-type calcium channel subunit alpha-1C, subunit, α1-AR, α1-adrenoceptor; α2-AR, α2-adrenoceptor; 5-HT, serotonin receptors; SLC22A1; SLC22A, solute carrier 22; type 1, 2, glycine, glycine receptors; D3DR, dopamine D3 receptors; DAT, dopamine transporter; H1R, H2R, H3R, histamine receptors 1, 2, and 3; NET, norepinephrine transporter; TRPA1, transient receptor potential ankyrin channel 1; Kv4.3, potassium channel; voltage-dependent, type 4.3; σOR, sigma opioid receptor; SERT, serotonin (5-HT) transporter; NMDAε2, ε2 subunit of NMDA; receptor; ACAT, acyl coenzyme A, cholesterol acyltransferase, BACE, 1, beta secretase 1; ChAc, choline acetylase; MAO A, B, monoamine oxidase A; B, σ1, σ1 receptor; CB1R, cannabinoid CB1, CB2 receptor; CYP2D6, cytochrome P450 2D6, GluN1; GluN2, glutamate NMDA, receptor (subunits 1 and 2); HNMT, histamine N-methyltransferase.
FIGURE 2Comparison of normal signaling and changes in socially isolated animals. (A): normal cholinergic signaling. (B): changes in molecules involved in cholinergic signaling in socially isolated animals. A decrease is shown as a diminished symbol in the red circle, and an increase is shown as an enlarged symbol in the green circle (e.g., ChAT). Positive effects targeting the structure are shown as green circles with green arrows. Positive effects targeting the structure are shown as red circles with red arrows. If there is no change in the activity/amount/activation, then the molecule is shown under normal conditions.
FIGURE 3Algorithm for MR subtype or NR subunit role in social isolations.